Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

vTv Therapeutics Inc.

www.vtvtherapeutics.com

Latest From vTv Therapeutics Inc.

CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

BioPharmaceutical Deals

Pipeline Watch: Phase III Starts For Seres' SER-109, Leo's Tralokinumab And Alkermes' ALKS-5461

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

vTv Therapeutics Seeks Big Pharma Partner For Oral GLP-1

US-based vTv Therapeutics says its oral small molecule GLP-1R agonist targeting HbA1c is unique and that big pharma players are keen to partner the compound.

Companies Metabolic Disorders

Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche

Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • TransTech Pharma Inc.
  • vTvx Holdings I LLC
  • vTV Therapeutics LLC
  • vTv Therapeutics Holdings LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • vTv Therapeutics Inc.
  • Senior Management
  • Stephen L Holcombe, BSc, Pres. & CEO
    Rudy C Howard , CFO
    Carmen Valcarce, PhD, SVP, CSO
    Aaron Burnstein, PharmD, SVP, Clinical Dev.
    Larry Altstiel, MD, PhD, CMO
  • Contact Info
  • vTv Therapeutics Inc.
    Phone: (336) 841-0300
    4170 Mendenhall Oaks Pkwy.
    High Point, NC 27265
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register